KAPA

Kairos Pharma Ltd

Add to Watchlist

Advanced Chart

0.930

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.9605

Open

0.9605

VWAP

0.94

Vol

495.84K

Mkt Cap

15.67M

Low

0.900

Amount

463.88K

EV/EBITDA(TTM)

Total Shares

16.85M

12.05M

EV/OCF(TTM)

P/S(TTM)

Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.

2 Analyst Rating

760.22% Upside

Wall Street analysts forecast KAPA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAPA is 8.00 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

760.22% Upside

Current: 0.930

Low

4.00

Averages

8.00

High

12.00

760.22% Upside

Current: 0.930

Low

4.00

Averages

8.00

High

12.00

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-17

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-17

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Initiates

$12

2025-04-03

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

$12

2025-04-03

Initiates

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-31

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-31

Maintains

Strong Buy

Reason

Maxim Group

Jason McCarthy

Strong Buy

Initiates

2025-03-27

Reason

Maxim Group

Jason McCarthy

Price Target

2025-03-27

Initiates

Strong Buy

Reason

Maxim analyst Jason McCarthy initiated coverage of Kairos Pharma with a Buy rating and $4 price target.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-20

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-20

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-02-26

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-02-26

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Kairos Pharma Ltd (KAPA.A) is -4.33, compared to its 5-year average forward P/E of -5.55. For a more detailed relative valuation and DCF analysis to assess Kairos Pharma Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.55

Current PE

-4.33

Overvalued PE

-3.03

Undervalued PE

-8.07

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.74

Current EV/EBITDA

-2.26

Overvalued EV/EBITDA

0.26

Undervalued EV/EBITDA

-1.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00